Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today

By Cory Renauer - Oct 4, 2017 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks like the share offering announced yesterday won't sting as bad as expected.

What happened

Shares of Rigel Pharmaceuticals, Inc. (RIGL 10.62%) got off to a rocky start this morning, falling more than 8% before the market digested the details of a recently announced share offering. The stock has since reversed course and was up about 12.7% at 3:01 p.m. EDT on Wednesday.

So what 

This biotech stock surged earlier this week when the FDA announced it would not require an advisory committee meeting to complete its review of Tavalisse for treatment of immune thrombocytopenic purpura (ITP). The company will need to assemble a sales force if the Agency greenlights the drug, and yesterday's secondary offering announcement wasn't unexpected.

Stock traders pointing to up at one of many monitors.

Image source: Getty Images.

As is usually the case, the stock started slipping as investors had no idea just how many shares the company intended to sell to raise "up to $40 million" in a public offering. The stock reversed course and headed higher once investors got their hands on a regulatory filing that assumes a public offering price of $3.37 per share, the stock's price at Monday's close.

Now what

According to Rigel, the company's outstanding share count will rise from 123.8 million at the end of June up to 137.5 million if the offering's underwriters purchase additional shares. That's a lot less dilution than investors had braced for, and it will beef up the company's dwindling cash balance that stood at just $82.3 million at the end of June.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
RIGL
$1.25 (10.62%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.